Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is gaining attention as a biotech stock supported by robust commercial results and pipeline advancements. The company posted a total revenue of $203.1 ...

This fund holds a portfolio of 75-125 biotechnology stocks ... bearish on Moderna's coronavirus vaccine and underweighted the stock in 2020 and 2021, which hurt the fund's relative performance ...

The improved sales of Nerlynx have been the primary reason for the stock’s increase in the past six months. Puma Biotechnology in-licensed the global development and commercialization rights to ...